What is the 13F Pro Quality Score for GYRE?

13F Pro ranks GYRE THERAPEUTICS, INC. (GYRE) on the 13F Pro Quality Score, a 0–100 composite of 32 fundamental signals including return on invested capital, free cash flow consistency, balance-sheet strength, earnings quality, growth durability, and valuation discipline. The score refreshes after each 10-K and 10-Q filing on SEC EDGAR. View GYRE's current score at https://13fpro.ai/research/GYRE (free sign-up required for the full ranking).

Where does 13F Pro source GYRE data?

All GYRE THERAPEUTICS, INC. fundamentals and ownership data come directly from SEC EDGAR. GYRE THERAPEUTICS, INC. files with the SEC under CIK 1124105. 13F Pro ingests XBRL financial facts from 10-K and 10-Q filings, Form 13F-HR institutional holdings, and Form 4 insider transactions, with no third-party rewrites or estimates.

What sector is GYRE in?

GYRE THERAPEUTICS, INC. (GYRE) is classified in the Healthcare sector. 13F Pro publishes sector-level fund flow analysis and quality leaders at https://13fpro.ai/research/sector/healthcare.

How often is GYRE research updated on 13F Pro?

GYRE's fundamentals refresh within hours of each new 10-K or 10-Q filing on SEC EDGAR. Institutional ownership updates after each quarterly 13F filing window. Insider transactions update after each Form 4 filing. The 13F Pro Quality Score recalculates after every fundamentals refresh.

GYRE THERAPEUTICS, INC.(GYRE)Stock Analysis

AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →

Healthcare →Nasdaq

Institutional-grade research for retail investors

SEC EDGAR: CIK 1124105 GYRE stock profile & AI dashboard →

13F Pro Quality Score

31.5/100

Rank #2,309 of 2,879 stocks

View Healthcare peers →

Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Aug 14, 2026.

Revenue Growth

10.2/100

Profitability

42.0/100

Balance Sheet

42.0/100

Earnings Quality

1.0/100

Free Cash Flow

59.4/100

Institutional Flow

40.2/100

Revenue Scale

17.7/100

Dilution Risk

22.9/100

GYRE Stock Analysis & AI Quality Score

AI stock analysis and institutional research for GYRE THERAPEUTICS, INC. (GYRE), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GYRE at 31.5/100 on a 32-signal composite quality model, placing it at rank #2,309 of 2,879 stocks — the bottom half of the AI-ranked universe. Areas of concern include earnings quality (1.0) and revenue growth (10.2), which score below median versus the broader universe. Shareholder dilution risk is elevated at 22.9/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), GYRE THERAPEUTICS, INC. reports quarterly revenue of $22.5M, net income of $-9.9M, free cash flow of $3.0M. Top institutional holders of GYRE by reported 13-F value include VANGUARD CAPITAL MANAGEMENT, BlackRock,, GEODE CAPITAL MANAGEMENT,, based on the most recent SEC filings. GYRE trades on the Nasdaq exchange and files with the SEC under CIK 1124105. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GYRE daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for GYRE THERAPEUTICS, INC. directly from SEC EDGAR. GYRE THERAPEUTICS, INC.'s 13F Pro composite quality score has ranged between 32 and 71 since 2024, currently 31.5 — a declining long-term trajectory across 16 quarterly and live scoring snapshots.

✦

Fun facts about GYRE THERAPEUTICS, INC.

Quirks, history, and lore behind GYRE — the kind of stuff that makes a stock memorable.

1
The Basics
A small-cap biopharmaceutical company · listed on Nasdaq · focused on developing therapies for fibrotic and inflammatory diseases.
2
The Numbers
Revenue in the range of tens of millions of dollars annually, with operations spanning both U.S. and China — a dual-market footprint unusual for a company this size.
3
The History
The company underwent a significant rebranding and strategic pivot in the early 2020s, shifting its identity toward fibrosis-focused drug development after earlier incarnations under a different name.
4
The Secret
Its lead pipeline leans heavily on compounds targeting TGF-β pathways — a biological mechanism tied to scarring and tissue damage that affects millions with liver and lung fibrosis.
5
The Lore
The company's name evokes a spiral or circular motion — apt for a biotech that keeps cycling back to the same stubborn disease biology that the rest of pharma hasn't cracked.
6
The Giveaway
Its ticker spells out a spinning ocean current, and its mission is to untangle the fibrotic web in diseases like NASH and IPF — this is Gyre Therapeutics.

▶ Think you know your stocks? Play the Daily Ticker

Revenue

Q1 2026

$22.5M

Net Income

Q1 2026

$-9.9M

Free Cash Flow

Q1 2026

$3.0M

Revenue & Net Income

Earnings Per Share

Key Financials Over Time

Export Financial Table · Pro+

Revenue

+10.2% YoY

$116.6MFY 2025

FY20 $20.9MFY23 $113.5MFY24 $105.8MFY25 $116.6M

Net Income

-44.8% YoY

$9.9MFY 2025

FY20 $-56.2MFY23 $-85.5MFY24 $17.9MFY25 $9.9M

Operating Income

-28.9% YoY

$11.5MFY 2025

FY20 $-57.4MFY23 $-67.2MFY24 $16.2MFY25 $11.5M

EPS (Diluted)

-60.0% YoY

$0.02FY 2025

FY20 —FY23 $-1.41FY24 $0.05FY25 $0.02

Total Assets

+32.5% YoY

$166.1MFY 2025

FY20 $94.8MFY23 $116.5MFY24 $125.4MFY25 $166.1M

Op. Cash Flow

+127.7% YoY

$1.0MFY 2025

FY20 $-55.0MFY23 $25.9MFY24 $-3.6MFY25 $1.0M

Metric	FY 2025	FY 2024	FY 2023	FY 2020	FY 2018	FY 2017
Revenue	$116.6M +10.2%	$105.8M -6.8%	$113.5M +441.6%	$20.9M +349033.3%	$6.0K -99.4%	$1.0M
Net Income	$9.9M -44.8%	$17.9M +120.9%	$-85.5M -52.0%	$-56.2M -87.1%	$-30.1M -39.4%	$-21.6M
Operating Income	$11.5M -28.9%	$16.2M +124.0%	$-67.2M -17.2%	$-57.4M -69.6%	$-33.8M -55.0%	$-21.8M
EPS (Diluted)	$0.02 -60.0%	$0.05 +103.5%	$-1.41	—	—	—
Total Assets	$166.1M +32.5%	$125.4M +7.6%	$116.5M +22.9%	$94.8M -24.1%	$124.9M +216.1%	$39.5M
Operating Cash Flow	$1.0M +127.7%	$-3.6M -114.1%	$25.9M +147.0%	$-55.0M -92.8%	$-28.6M -43.2%	$-19.9M

AI Insight: GYRE Financial Trends

Q1 2026 swings to a $10M net loss and $9M operating loss, erasing six quarters of profitability momentum despite steady equity build.

• Revenue reached a peak of $37M in Q4 2025 but fell sharply to $23M in Q1 2026, near the lowest level in the dataset.

• Operating income collapsed from $7M in Q3 2025 to $0M in Q4 2025 and -$9M in Q1 2026 — a dramatic three-quarter deterioration.

• Equity expanded from $60M in Q2 2024 to $106M in Q4 2025, though it dipped to $101M in Q1 2026 on the net loss.

• Operating cash flow turned positive at $3M in Q1 2026, diverging from the large net and operating losses that quarter.

⚠ Q1 2026 net loss of $10M is the worst in the dataset — confirm whether this reflects a one-time charge or structural cost shift.

⚠ Revenue volatility is high, ranging $22M–$37M over eight quarters; Q1 2026's $23M suggests potential seasonal or pipeline risk.

⚠ Total debt remains unreported across all periods — absence of leverage data limits full balance-sheet risk assessment.

AI Insight: GYRE Ratio Trends

Q1 2026 marks a severe inflection: operating margin collapsed to -41.5% and ROIC to -36.9%, erasing prior profitability entirely.

• Operating margin swung from a peak of 22.7% in Q3 2025 to -41.5% in Q1 2026 — a 64pp deterioration in two quarters.

• ROIC turned deeply negative at -36.9% in Q1 2026, versus 27.2% in Q3 2025, signaling capital is now being destroyed.

• Net profit margin fell to -43.8% in Q1 2026 from 19.3% in Q3 2025, the sharpest single-quarter deterioration in the dataset.

• TTM operating margin stands at -0.1%, masking Q1 2026's sharp losses due to stronger earlier quarters in the trailing period.

⚠ Q1 2026 ROE hit -38.9% and ROA -24.3% — first time both turned deeply negative; sustainability of the business model is now in question.

⚠ D/E data is absent throughout; understanding leverage structure is critical given the sudden shift to large operating losses.

⚠ Quarter-to-quarter volatility is extreme — Q4 2025 margin was 0.3% before collapsing to -41.5% in Q1 2026; watch for one-off charges driving distortion.

Get alerted when GYRE's score changes

Free account: watchlist tracking, the daily AI brief, and the AI screener.

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Available Research

13F Pro tracks comprehensive data for GYRE THERAPEUTICS, INC. including:

SEC EDGAR filings (10-K, 10-Q, 8-K)

XBRL financial facts (revenue, EPS, margins)

Insider transactions (Form 4)

Institutional 13F holdings

Quality rankings (32 signals)

AI analyst debates & daily meetings

Historical financial trends

Peer comparison & sector analysis

Top Institutional Holders of GYRE

VANGUARD CAPITAL MANAGEMENT LLC
$6.9M984,204 sh
BlackRock, Inc.
$5.3M758,630 sh
GEODE CAPITAL MANAGEMENT, LLC
$3.0M431,414 sh
STATE STREET CORP
$1.5M216,326 sh
SBI Securities Co., Ltd.
$1.2M170,837 sh
CHARLES SCHWAB INVESTMENT MANAGEMENT INC
$1.2M165,238 sh
VANGUARD FIDUCIARY TRUST CO
$959.6K137,682 sh
NORTHERN TRUST CORP
$932.9K133,841 sh
GOLDMAN SACHS GROUP INC
$509.7K73,122 sh
VANGUARD PORTFOLIO MANAGEMENT LLC
$486.6K69,814 sh

Fund	Value	Shares
VANGUARD CAPITAL MANAGEMENT LLC	$6.9M	984,204
BlackRock, Inc.	$5.3M	758,630
GEODE CAPITAL MANAGEMENT, LLC	$3.0M	431,414
STATE STREET CORP	$1.5M	216,326
SBI Securities Co., Ltd.	$1.2M	170,837
CHARLES SCHWAB INVESTMENT MANAGEMENT INC	$1.2M	165,238
VANGUARD FIDUCIARY TRUST CO	$959.6K	137,682
NORTHERN TRUST CORP	$932.9K	133,841
GOLDMAN SACHS GROUP INC	$509.7K	73,122
VANGUARD PORTFOLIO MANAGEMENT LLC	$486.6K	69,814

More Healthcare Companies

View all Healthcare →

AAPG

ASCENTAGE PHARMA GROUP INTERNATIONAL

AARD

Aardvark Therapeutics, Inc.

ABBV

AbbVie Inc.

ABCL

AbCellera Biologics Inc.

ABEO

ABEONA THERAPEUTICS INC.

ABOS

Acumen Pharmaceuticals, Inc.

ABPWW

Abpro Holdings, Inc.

ABSI

Absci Corp

Put GYRE on your watchlist

Track score changes the day GYRE THERAPEUTICS, INC. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.

View Pricing

Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).

Passwordless sign-in · Payments by Stripe · Auth by Clerk

Popular Research

AAPL

Apple

MSFT

Microsoft

NVDA

NVIDIA

GOOG

Alphabet

AMZN

Amazon

Is GYRE a good stock to buy?

13F Pro's AI-powered analysis of GYRE THERAPEUTICS, INC. (GYRE) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for GYRE are available on the GYRE stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing.

Which hedge funds own GYRE?

Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling GYRE. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of GYRE THERAPEUTICS, INC.'s investment landscape.